Monday, March 18, 2024, San Diego, California, 12:15 PM – 1:45 PM Pacific Time (3:15 PM – 4:45 PM Eastern Time)

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Endometrial Cancer

Part 2 of a 2-Part CME Symposium Series Held in Conjunction with the 2024 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer®

Location
San Diego Convention Center
111 Harbor Drive
San Diego, California
Phone: (619) 525-5000

Program Schedule — Pacific Time
11:45 AM – 12:15 PM — Registration
and Lunch Buffet
12:15 PM – 1:45 PM — Educational Meeting

Meeting Room
Ballroom 20AB (Upper Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.  
 
Faculty
Nicoletta Colombo, MD
Director, Gynecologic Oncology Program
European Institute of Oncology IRCCS
University of Milano-Bicocca
Milan, Italy

Matthew A Powell, MD
Professor, Department of Obstetrics
and Gynecology
Washington University School of Medicine
St Louis, Missouri

Brian M Slomovitz, MD
Professor, OB-GYN, Florida International University
Director, Gynecologic Oncology
Co-Chair, Cancer Research Committee
Mount Sinai Medical Center
Miami, Florida

Moderator
Shannon N Westin, MD, MPH, FASCO, FACOG
Professor
Medical Director, Gynecologic Oncology Center
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Karyopharm Therapeutics.
Program Schedule — Pacific Time
11:45 AM – 12:15 PM — Registration and Lunch Buffet
12:15 PM – 1:45 PM — Educational Meeting

MODULE 1: Current Approaches to First-Line Therapy for Advanced Endometrial Cancer (EC) — Prof Colombo

  • Incidence of microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) advanced EC; appropriate methods for and timing of testing
  • Similarities and differences among the designs, eligibility criteria and endpoints of the Phase III RUBY, NRG-GY018 and AtTEnd trials evaluating dostarlimab, pembrolizumab and atezolizumab, respectively, in combination with chemotherapy as first-line treatment for advanced or recurrent EC
  • Published efficacy and safety results from the RUBY, NRG-GY018 and AtTEnd trials; outcomes achieved among various patient subsets
  • Recent FDA approval of dostarlimab in combination with chemotherapy for patients with MSI-H/dMMR EC; optimal incorporation into current management algorithms
  • Recent announcement of the failure of the Phase III LEAP-001 trial evaluating pembrolizumab/lenvatinib in the up-front setting; implications for current practice and future research

MODULE 2: Novel Investigational Strategies for Newly Diagnosed EC — Dr Westin

  • Biological rationale for the evaluation of PARP inhibition in advanced EC; possible therapeutic synergy between PARP inhibitors and anti-PD-1/PD-L1 antibodies
  • Key efficacy and safety data from the Phase III DUO-E trial evaluating first-line durvalumab in combination with chemotherapy followed by durvalumab maintenance with or without olaparib for patients with newly diagnosed advanced or recurrent EC
  • Similarities and differences between the designs of DUO-E and Part 2 of the RUBY trial; recent announcement of a progression-free survival benefit with dostarlimab/niraparib maintenance in RUBY Part 2
  • Potential role of anti-PD-1/PD-L1 antibodies in combination with PARP inhibitors in the care of patients with EC
  • Mechanism of action of selinexor and scientific rationale for its evaluation in EC
  • Efficacy and safety findings from the Phase III SIENDO trial evaluating selinexor as maintenance therapy after first-line chemotherapy for patients with advanced or recurrent EC; outcomes achieved in the p53 wild-type subgroup
  • Design, eligibility criteria and key endpoints of the Phase III XPORT-EC-042 trial assessing selinexor maintenance after first-line chemotherapy for p53 wild-type advanced EC; estimated completion date

MODULE 3: Current Options for Relapsed/Refractory EC — Dr Slomovitz

  • Key data with dostarlimab and pembrolizumab monotherapy for patients with MSI-H/dMMR advanced EC
  • Long-term efficacy and safety findings from the Phase III KEYNOTE-775 trial comparing pembrolizumab/lenvatinib to chemotherapy for patients with advanced EC who previously received treatment with a platinum-based regimen
  • Optimal integration of pembrolizumab/lenvatinib into current EC management algorithms
  • Incidence and management of toxicities with pembrolizumab/lenvatinib
  • Other novel agents and strategies under evaluation for the treatment of advanced EC

MODULE 4: Role of HER2-Targeted Therapy in the Management of Advanced EC — Dr Powell

  • Frequency of HER2 expression in advanced EC; optimal timing of and approach to testing
  • Published clinical research studies supporting the use of trastuzumab as a component of therapy for HER2-positive uterine serous carcinoma and carcinosarcoma
  • Early data with other HER2-targeted strategies for advanced EC, such as findings from the Phase II STATICE trial and the TAPUR basket trial
  • Efficacy and safety outcomes achieved with trastuzumab deruxtecan among patients with advanced EC in the DESTINY-PanTumor02 study
  • Implications of the DESTINY-PanTumor02 study for biomarker evaluation and clinical management of advanced EC

Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of endometrial cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate the importance of microsatellite instability (MSI) and mismatch repair (MMR) deficiency assessment for patients with endometrial cancer, and adapt current testing practices to effectively identify individuals with these genetic abnormalities.
  • Appreciate available research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer, and consider the current and potential role of this novel strategy in the care of patients with MSI-high/MMR-deficient or microsatellite-stable/MMR-proficient disease.
  • Review the benefits observed with anti-PD-1/PD-L1 antibodies as monotherapy for MSI-high/MMR-deficient endometrial cancer, and appropriately integrate these agents into the care of patients with relapsed/refractory disease.
  • Recognize available and emerging data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and select patients with metastatic endometrial cancer for this novel therapeutic approach.
  • Understand the biological rationale for and available and emerging data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for advanced or metastatic endometrial cancer.
  • Evaluate published clinical research documenting the efficacy of HER2-targeted agents and regimens in patients with HER2-overexpressing endometrial cancer, and consider the role of various approaches in disease management.
  • Describe the scientific justification for, published research data with and current studies evaluating novel agents and strategies for endometrial cancer, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Colombo — Advisory Committees: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GSK, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, MSD, Novocure Inc, Nuvation Bio, OncXerna Therapeutics Inc, Pieris Pharmaceuticals Inc, Roche Laboratories Inc; Consulting Agreements: MSD, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, GSK; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GSK, Merck, MSD. Dr Powell — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, ImmunoGen Inc, Merck, Seagen Inc. Dr Slomovitz — Consulting Agreements: Aadi Bioscience, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, ImmunoGen Inc, Merck, Novocure Inc; Speakers Bureau: Seagen Inc; Nonrelevant Financial Relationship: GOG Foundation Inc.

MODERATOR — Dr Westin — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Clovis Oncology, Eisai Inc, EQRx, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, Mersana Therapeutics Inc, NGM Biopharmaceuticals, Nuvectis Pharma Inc, pharmaand GmbH, Seagen Inc, Verastem Inc, Vincerx Pharma, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings, Clovis Oncology, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals Inc, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, pharmaand GmbH, Zentalis Pharmaceuticals.

VIDEO PARTICIPANTS — Floor J Backes, MD — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, BioNTech SE, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, GSK, ImmunoGen Inc, Merck. Ritu Salani, MD, MBA — Advisory Committees: Eisai Inc, GSK, ImmunoGen Inc, Merck, Regeneron Pharmaceuticals Inc, Seagen Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Karyopharm Therapeutics.

San Diego Convention Center
111 Harbor Drive
San Diego, CA 92101
Phone: (619) 525-5000

Meeting Room
Ballroom 20AB (Upper Level)

Directions
The San Diego Convention Center is the main venue for the 2024 SGO Annual Meeting on Women’s Cancer.

This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of endometrial cancer.

There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2024 SGO Annual Meeting on Women’s Cancer.

IN-PERSON Registration for clinicians in practice/healthcare professionals

Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 11:45 AM PDT on Monday, March 18th. If you are interested in attending, please visit our registration desk outside the Room 30 ABCDE (Upper Level) at the San Diego Convention Center (111 Harbor Drive). Please note: Seats will be offered on a first come, first served basis, and onsite registration does not guarantee participation in the meal service. Clinicians in practice will be prioritized for seating first.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

LIVE WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.